Literature DB >> 21940621

Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism.

Sabina Pappatà1, G Santangelo, D Aarsland, C Vicidomini, K Longo, K Bronnick, M Amboni, R Erro, C Vitale, M G Caprio, M T Pellecchia, A Brunetti, G De Michele, M Salvatore, P Barone.   

Abstract

OBJECTIVE: To characterize brain metabolic changes associated with mild cognitive impairment (MCI) in drug-naive patients with Parkinson disease (PD) using (18)F-fluorodeoxyglucose (FDG) and PET (FDG-PET).
METHODS: This cross-sectional study included newly diagnosed patients with PD with MCI in single or multiple domain (PD-MCI; n =12) and without MCI (PD-nMCI; n =12), and healthy controls (n =12). The groups were matched for age. Moreover, the patient groups were matched for motor disability. All subjects underwent a FDG-PET study. Cerebral regional relative metabolic maps were compared in PD-MCI, PD-nMCI, and controls using regions of interest analysis (ROIs) and voxel-based analysis with statistical parametric mapping.
RESULTS: ROIs and voxel-based analyses revealed significant relative hypometabolism in the prefrontal, superior/inferior parietal, and associative occipital cortices as well as in the striatum in patients with PD-MCI relative to controls (p < 0.05) and to a lesser extent in patients with PD-nMCI. In contrast, patients with PD-nMCI did not show significant metabolic changes as compared to controls.
CONCLUSION: MCI in patients with PD is associated with cortical hypometabolism since the earliest stage, independent of therapy or motor disability. The early involvement of posterior cortical region, a pattern shared by advanced stages of PD-MCI and PD with dementia, could represent an early marker of dementia. The relevance of this pattern in predicting prodromal dementia has to be evaluated in longitudinal studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940621     DOI: 10.1212/WNL.0b013e3182315259

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

3.  Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.

Authors:  David Garcia-Garcia; Pedro Clavero; Carmen Gasca Salas; Isabel Lamet; Javier Arbizu; Rafael Gonzalez-Redondo; Jose A Obeso; Maria C Rodriguez-Oroz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-08       Impact factor: 9.236

4.  Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

Authors:  Rafael González-Redondo; David García-García; Pedro Clavero; Carmen Gasca-Salas; Reyes García-Eulate; José L Zubieta; Javier Arbizu; José A Obeso; María C Rodríguez-Oroz
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

5.  Arterial spin labelling detects posterior cortical hypoperfusion in non-demented patients with Parkinson's disease.

Authors:  Zoe Joanna Syrimi; Lubomir Vojtisek; Ilona Eliasova; Jana Viskova; Alena Svatkova; Jiri Vanicek; Irena Rektorova
Journal:  J Neural Transm (Vienna)       Date:  2017-03-07       Impact factor: 3.575

Review 6.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

7.  Abnormal metabolic pattern associated with cognitive impairment in Parkinson's disease: a validation study.

Authors:  Sanne K Meles; Chris C Tang; Laura K Teune; Rudi A Dierckx; Vijay Dhawan; Paul J Mattis; Klaus L Leenders; David Eidelberg
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-10       Impact factor: 6.200

8.  Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease.

Authors:  Marianna Amboni; Alessandro Tessitore; Fabrizio Esposito; Gabriella Santangelo; Marina Picillo; Carmine Vitale; Alfonso Giordano; Roberto Erro; Rosa de Micco; Daniele Corbo; Gioacchino Tedeschi; Paolo Barone
Journal:  J Neurol       Date:  2014-11-27       Impact factor: 4.849

Review 9.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 10.  PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.

Authors:  Robert W Gould; Angela N Duke; Michael A Nader
Journal:  Neuropharmacology       Date:  2013-02-28       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.